← Back
Data updated: Mar 10, 2026
EMD SERONO INC
OncologyNeurologyImmunology
EMD SERONO INC is a biotechnology company focused on Oncology, Neurology, Immunology. Key products include BAVENCIO.
1982
Since
18
Drugs
-
Trials
8
Approved (2yr)
Key Drugs
Recent Activity
BAVENCIO 2025-06-04
Labeling
BAVENCIO 2024-11-26
Labeling
CETROTIDE 2024-11-18
Manufacturing (CMC)
BAVENCIO 2024-10-11
Efficacy
CETROTIDE 2024-06-04
Labeling
GONAL-F RFF REDI-JECT 2024-05-13
Labeling
GONAL-F RFF REDI-JECT 2024-05-13
Labeling
MAVENCLAD 2024-05-10
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 72%
1 drugs Phase 3: 9 Phase 2: 12 Phase 1: 34
Neurology 12%
1 drugs Phase 3: 2 Phase 2: 1 Phase 1: 1
Immunology 7%
0 drugs Phase 2: 4 Phase 1: 1
Metabolic 4%
1 drugs
Gastroenterology 4%
0 drugs Phase 3: 1 Phase 1: 2
Pipeline Strength Pro
Loading...
Competitors Pro
Takeda big-pharma
Immunology, Oncology, Gastroenterology, Neurology, Metabolic
Eli Lilly big-pharma
Metabolic, Oncology, Immunology, Neurology
Amgen biotech
Oncology, Immunology, Metabolic, Gastroenterology, Neurology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology, Neurology
Pfizer big-pharma
Oncology, Immunology, Gastroenterology
Discontinued (10)
Company Info
- First Approval
- 1982-03-22
- Latest
- 2025-06-04
- Applications
- 19
FDA Sponsor Names
EMD SERONO INCEMD SERONO